Cerity Partners OCIO’s ADMA Biologics ADMA Stock Holding History

Cerity Partners OCIO’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$39K	Hold	10,000	–	–	﹤0.01%	421
2022 Q3	$24K	Hold	10,000	–	–	﹤0.01%	411
2022 Q2	$20K	Sell	10,000 -75	-0.7%	-$148	﹤0.01%	416
2022 Q1	$18K	Buy	10,075 +75	+0.8%	+$117	﹤0.01%	419
2021 Q4	$14K	Hold	10,000	–	–	﹤0.01%	415
2021 Q3	$11K	Hold	10,000	–	–	﹤0.01%	408
2021 Q2	$16K	Buy	+10,000	New	+$17.6K	﹤0.01%	388

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cerity Partners OCIO's ADMA Position: Q4 2022 in Review

Cerity Partners OCIO held its ADMA Biologics (ADMA) position steady in Q4 2022 at 10,000 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #421.

Cerity Partners OCIO first reported a position in ADMA in Q2 2021 and has held it in 7 quarters since. 159 funds tracked by Wall St. Rank hold ADMA as of Q4 2022.

Cerity Partners OCIO held 10,000 shares of ADMA Biologics worth $39K as of Q4 2022.
Cerity Partners OCIO left its ADMA Biologics share count unchanged in Q4 2022.
ADMA Biologics made up ﹤0.01% of Cerity Partners OCIO's portfolio in Q4 2022, its #421 holding.
Cerity Partners OCIO first reported a position in ADMA Biologics in Q2 2021 and has held it in 7 quarters since.
159 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2022.

Based on Cerity Partners OCIO's 13F filing for Q4 2022, filed 2 Feb 2023.